Sage Journals: Discover world-class research

Abstract

Background and objective:

Breast cancer liver and lung metastases are common and associated with poor prognosis. Personalized medical treatment of advanced breast cancer, based on established predictive factors, has improved survival during the last decades. In contrast, there is no consensus regarding indications for surgery. The aim of this narrative review is to summarize the current knowledge on the outcome of surgical treatments for breast cancer liver and lung metastases.

Method:

A narrative review of existing evidence for diagnosis and treatment of breast cancer liver and lung metastases.

Results:

There are no randomized trials to evaluate surgery as an adjunct to medical treatment. In this review, data are reported from case–control studies and meta-analyses on surgery for liver and lung metastases. Selected patients have an improved survival after surgery compared to those who only received medical treatment. The survival benefit is, however, uncertain when adjusting for prognostic factors, and prospective trials are warranted. Anecdotal cases have long-term survival and surgery is safe.

Conclusion:

Surgery for breast cancer liver and lung metastases may be considered in selected cases within prospective studies.

Keywords

Breast cancer liver metastasis pulmonary metastasis

Context and relevance

Breast cancer is a common disease, but the benefit of local treatment of distant metastases remains unclear. There are several case series published suggesting improved survival after surgical treatment of breast cancer metastases, but there is still a lack of large, randomized trials to rule out selection bias. Lung and liver are the second and third most common sites for breast cancer metastases. This narrative review summarizes the current knowledge on the diagnosis and surgical treatment of disseminated breast cancer and describes the modalities for local treatment in the lung and the liver. Recent studies highlight both the importance of patient selection prior to treatment and the need for prospective trials.

Introduction

Breast cancer is the leading cause of cancer-related death among women in the world.¹ Screening programs combined with modern surgical and oncological treatment strategies have improved survival among breast cancer patients in developed countries.² Still, the breast cancer mortality is constant due to an increased incidence.³ Systemic disease may ultimately result in visceral crisis and death.⁴

Locoregional breast cancer is associated with excellent survival rates while the prognosis remains dismal in metastatic disease.³ The St. Gallen classification of molecular breast cancer subtypes has prognostic value and predicts response to oncological and endocrine treatments. The classification is based on the Nottingham histologic grade (NHG), the proliferation marker Antigen Kiel 67 (Ki-67) and expression of estrogen receptors (ERs), progesterone receptors (PgRs), and amplification of human epidermal growth factor receptor 2 (HER2) gene.⁵ Expression of ER and PgR is associated with improved prognosis,⁶ while the oncogene HER2 has a treatment predictive value owing to targeted anti-HER2 therapy.⁷ Still, metachronous metastases may arise long after primary diagnosis, even in patients with a favorable breast cancer subtype. This results in long-term anxiety for relapse among breast cancer patients. Bone is the most common site of distant spread, particularly in estrogen receptor-positive cancer. These patients respond well to endocrine treatment, and progression can often be delayed for years.⁸

Breast cancer lung and liver metastases are the second and third most common metastases, respectively.⁸ This visceral spread is associated with poor prognosis.⁹ The median survival is estimated to be approximately 30 months. Breast cancer cells with HER2 amplification or loss of hormonal receptor expression are more common in these sites, compared to bone.^8,9 The hormonal receptor status may also convert between the primary tumor and the metastases, leading to another, often more aggressive, molecular subtype in the metastases.^10–14

Surgical treatment of breast cancer metastases is debated. Advanced breast cancer, with spread beyond locoregional lymph nodes, is normally considered a systemic disease, and there are no general recommendations for surgery.⁴ Numerous case series and retrospective studies have, however, suggested that surgical treatment may improve survival in selected patients, especially in an oligometastatic setting.^15–26 In an era of improved medical treatment for advanced breast cancer, it is important to ask whether surgery improves survival? This review summarizes the current knowledge regarding the outcome of local treatment of breast cancer liver and lung metastases.

Diagnosis of breast cancer metastases

Synchronous distant metastases are diagnosed during initial staging examinations and primarily result in recommendation on systemic treatment. If the primary breast cancer is asymptomatic, it is often left without surgical treatment. There is no general surveillance guideline for early diagnosis of metachronous distant metastases in early locoregional cancer. Instead, these may be diagnosed as incidental findings, due to symptoms or clinical suspicion based on risk assessment.⁴ The tumor marker Ca15-3 may also indicate disease progression.²⁷

Surgery of metastases is normally restricted to a limited spread, termed oligometastases, and often defined as 1–5 lesions. De novo oligometastases are separated from induced oligometastases when multiple lesions have vanished after medical treatment and ≤5 remain.²⁸ Prior to surgical resection, a detailed map of the disease is of outmost importance, and a positron emission tomography (PET) can be considered for optimal staging.⁴ Magnetic resonance imaging (MRI) with liver-specific contrast and diffusion-weighted images has the highest sensitivity for liver metastases,²⁹ while computed tomography (CT) is enough for pulmonary metastases.³⁰ Surgery is mostly considered after response to systemic treatment, and the RECIST-criteria can be applied to determine treatment response.³¹ In contrast to surgical treatment of colorectal liver and lung metastases, a biopsy of breast cancer metastases is always motivated. This is due to a frequent shift in the molecular subtype between the primary tumor and metastases. In 21% of patients, liver metastases have a different subtype than the primary tumor and most commonly a loss of hormonal receptor expression or gain of HER2 amplification (Fig. 1).¹⁰ Regarding lung metastases, a biopsy is also warranted to discriminate a metastatic lesion from a primary lung cancer.³² Breast cancer patients have an increased risk of lung cancer (standard incidence rate 1.4).³³ Furthermore, it is reported that adjuvant radiotherapy after breast surgery increases the risk of lung cancer, compared to breast surgery alone (relative risk 1.5).^34,35

Fig. 1.

Conversion of subtype in breast cancer liver and lung metastases. Estrogen receptor (ER) and human epidermal growth factor receptor-2 (HER2) status may convert from primary tumor to metastases. For example, a HER2 negative (neg) primary tumor may establish metastases with HER2 amplified (amp) cells.

Outcome of surgery for liver metastases

There are no randomized trials evaluating surgical treatment in addition to standard oncological treatment regimens for liver metastases specifically. One trial was recently closed due to a low inclusion rate.³⁶ The population of surgical candidates with isolated oligometastases is probably limited. We previously analyzed data from the Swedish National Register for Cancer in the Liver and Bile Duct and identified only 29 patients operated in Sweden during 2009–2016. Surgery was safe with no reported 90-day mortality. Median overall survival was 77 months from diagnosis of breast cancer liver metastases (BCLM). A control group with isolated oligometastases without surgical treatment had significantly shorter survival (28 months, p = 0.004). However, when adjusting for hormonal receptor status and HER-2 amplification, the hazard ratio in favor of surgery failed to reach statistical significance (hazard ratio (HR) = 0.48 95%confidence interval (CI) = 0.19–1.18, p = 0.11).²¹ There are several case reports, case series, and retrospective case–control series published, and most of them report improved outcomes from surgical treatment in selected patients. Table 1 summarizes the results of studies with a control group.

Table 1.

Retrospective studies of surgical treatment of breast cancer liver metastases.

Author	Inclusion	Country	Number	Median OS (m)	Comment
Author	Inclusion	Country	Surgery/control	Surgery/control	Comment
Sadot²⁴	1991–2014	The United States	69/98	50/45	PSM-analysis. No difference in survival.
Abbas²³	2005–2016	The United Kingdom	23/38	49/20	Multiple and large BCLM and more EHM in the control group.
Sundén²¹	2009–2016	Sweden	29/33	77/28	Less ER+ and shorter disease-free interval in the control group.
Chun²⁵	1997–2016	The United States	136/763	69/28	Improved 5-year survival after surgery in PSM of 72/72 patients.
Feng²⁶	2008–2018	China	33/119	62/38*	PSM-analysis. Benefit from surgery also in multivariate analysis.

Studies with a control group, published during the last 10 years, including >50 patients in total and reporting data on overall survival (OS) in months (m) are included.

PSM: propensity score match. ER+: estrogen receptor positive. BCLM: breast cancer liver metastases. EHM: extrahepatic metastases.

Mean OS.

A meta-analysis of case–control studies reported 46.0% 5-year survival after surgery, compared to 24.7% after systemic treatment only (p < 0.001).³⁷ Selection bias in the original studies cannot, however, be ruled out. The ESO-ESMO International Consensus Guideline for Advanced Breast Cancer recommends surgical resection or ablation only in highly selected patients with oligometastases isolated to the liver and after response to systemic treatment.⁴

Ablation, transarterial treatment, and radiotherapy of liver metastases

In addition to liver resection, there are several options for local treatment of liver metastases, and these are illustrated in Fig. 2. Radio frequency or microwave ablations are thermal techniques to destroy tumor tissue. These are established in adjunction to liver resection for the treatment of hepatocellular carcinoma (HCC) and colorectal liver metastases.³⁸ Percutaneous needle placement is guided by ultrasound or CT and navigation systems. Ablation is also an option during laparotomy or laparoscopy, either as a single intervention or in combination with liver resection. Superficial lesions can only be targeted with caution of surrounding tissues, and destruction of hilar metastases may result in bile duct injuries or cancer relapse due to survival of cancer cells close to a cooling blood stream in larger vessels. Yet, ablative treatment is associated with minor morbidity, compared to liver resection, and is often a treatment of choice for lesions up to 3 cm.^39,40 Zou et al.⁴¹ recently reported 132 patients with ablative treatment and did a propensity scored match in a control cohort of 836 patients. Among patients with up to three liver metastases <3 cm, median overall survival was 65.5 months in the ablation cohort, compared to 40.4 months in the matched control group (p = 0.003).

Fig. 2.

Local treatment modalities of liver and lung metastases.

Trans-arterial chemo-embolization (TACE) is an established treatment for local control or down-sizing of HCC, but there is no evidence to support treatment of breast cancer liver metastases outside clinical trials. A single-center study reported the median survival of 0.8 years in 549 patients, although the survival was better in patients with multimodal interventions including ablations.⁴² Trans-arterial radio-embolization (TARE) with yttrium-90 microspheres is another therapy for HCC, and it has also been tested for breast cancer liver metastases. Experimental TACE and TARE treatments have mostly been applied after the development of resistance to standard medical treatment. The benefit of these treatments is uncertain in patients with late stages of breast cancer.⁴³

Stereotactic body radiation therapy (SBRT) may be an option to treat liver metastases when other local therapies are unavailable. Most studies on SBRT, however, are case series with diverse origin of the primary tumors. While these studies show that local control can be obtained with acceptable toxicity, there is no evidence for improved survival rates.⁴⁴ Franceschini et al.⁴⁵ recently shared results from a prospective phase II trial on SBRT for up to four liver or lung metastases and report 51.9% overall survival and 16% distant metastases-free survival after 3 years.

Outcome of surgery for lung metastases

Pulmonary metastasectomy is rare, but when performed, it is usually restricted to minor sublobar resections. The indication for mediastinal lymph node dissection is controversial due to the lack of evidence for a survival benefit.⁴⁶

A German study of 81 patients operated for lung metastases between 1982 and 2007 showed improved survival compared to control groups matched for age and TNM-stage or age and hormone receptor status. Importantly, a small proportion of patients survived more than 10 years after metastasectomy.⁴⁷ A similar small Korean study by Yhim et al.⁴⁸ reported 82% 4-year survival after metastasectomy, compared to 31.6% in a control group (p = 0.001). A systematic review summarized nine studies of lung surgery for breast cancer metastases and the 5-year survival ranged from 35% to 72%.⁴⁹ They also identified prognostic factors frequently reported in the studies, including the disease-free interval, the number of metastases, complete R0 resection, and hormone receptor status. Of note is that most patients were operated more than 20 years ago.

Radiotherapy and ablation for lung metastases

SBRT has emerged as an option to treat oligometastases and is most frequently used against bone-, lung-, and lymph node metastases.⁵⁰ SBRT is generally safe and among 1597 patients (whereof 227 with breast cancer), SBRT was associated with 0.5% acute grade ≥3 adverse events.⁵¹ SBRT can result in local control of the disease, but the effect on survival remains to be determined. Local control is, however, associated with improved survival.⁴⁵ CT-guided percutaneous ablation of lung metastases has been evaluated in colorectal cancer and may be part of a multimodal treatment approach.⁵² Regarding breast cancer lung metastases, there are only minor case series published on ablation and the treatment can be associated with adverse events such as pneumothorax, pleural effusion, and infection.⁵³

Discussion

Metastatic breast cancer is a common cause of cancer-related death in women.³ While diagnostics and medical treatments improve, there is still a general lack of knowledge regarding the value of local treatment for oligometastases in the lung and liver. International guidelines state that prospective trials are urgently needed.⁴ However, randomization may be challenging due to a low incidence of patients fulfilling suggested inclusion criteria such as limited disease burden, metastases amenable to local treatment, preserved performance status, and response to treatment. In addition, randomization demands acceptance and compliance from study participants. Chmura et al.⁵⁴ have presented an abstract from a randomized trial on local treatment for 1–4 extracranial metastases. In the experimental arm, most had SBRT and only 1/60 had a surgical resection. The addition of local treatment to standard systemic therapies had no impact on progression-free or overall survival. International guidelines do not recommend routine ablation of asymptomatic oligometastases outside of clinical trials.⁵⁵ Current studies mainly focus on SBRT,⁵⁶ and the Taormina-trial⁵⁷ is still recruiting participants in Sweden. This study includes patients with up to five metastases in one or two organs and randomizes between SBRT toward all metastases or systemic treatment alone in a 2:1 ratio. A study design of multimodal treatments of oligometastatic breast cancer may be feasible to answer the question of if local treatments improve outcomes. Glemarec et al.⁵⁸ recently presented this in a single institution study and reported a hazard ratio (HR) 0.31 in favor of local ablative techniques compared to systemic treatment only.

Surgical treatment of breast cancer metastases may be valid in highly selected patients. It should only be performed after thorough discussions at multidisciplinary team (MDT) conferences and preferably within prospective studies. The MDT should consider performance status, disease-free interval, response to systemic treatment, and prognostic factors. Estrogen-positive breast cancer is a positive prognostic factor and predictive for response to endocrine treatments. HER-2 amplified breast cancer cells have a more aggressive phenotype and may thrive in viscera, but that are also sensitive to targeted anti-HER-2 treatment. Accordingly, we recently reported that HER-2 amplification was associated with improved survival among patients with breast cancer liver metastases.¹⁰

Future advancements in diagnostics and improved knowledge about recurrence patterns may enable early detection of metastases. For example, circulating tumor DNA (ctDNA) can be detected in blood due to the release of fragmented DNA from necrotic and apoptotic tumor cells. The level of ctDNA is reflected by tumor size and can monitor treatment response.⁵⁹ It holds prognostic value at an early stage of the disease and at the time of relapse. ctDNA has also been assessed for surveillance of relapses, yet with conflicting results.^60–62 Artificial intelligence (AI) models are also under development to predict distant metastases in breast cancer.⁶³

Due to the uncertain survival benefit, metastasectomy must be safe and associated with few complications. Minimally invasive strategies like video-assisted thoracoscopic surgery (VATS) and laparoscopic or robotic liver resection should be considered to minimize the surgical trauma. Ablative techniques may also enable local control of the disease and are associated with lower risk than operative resections. If local control can be obtained, it might provide improved quality of life and temporary cessation of heavy oncological treatment even if a survival benefit is uncertain.

In conclusion, surgical treatment of visceral breast cancer metastases should only be performed in highly selected patients. All operative and ablative local treatments of breast cancer metastases should be included in prospective trials.

Footnotes

Author contributions

O.H. drafted the article, and E.H. and C.W. revised it critically. All made a substantial contribution and approved the manuscript.

Authors’ note

Social media summary: This narrative review on local treatment of breast cancer liver and lung metastases shows that selected patients may be operated but preferably within prospective trials.

Declaration of conflicting interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was supported by research funds from Region Västerbotten (ALF-means).

ORCID iDs

Charlotta Wadsten

Oskar Hemmingsson

References

World Health Organization: Breast cancer. www.who.int/news-room/fact-sheets/detail/breast-cancer (2024, accessed February 19, 2025)

Torre

Siegel

Ward

, et al: Global cancer incidence and mortality rates and trends—an update. Cancer Epidemiol Biomarkers Prev 2016;25(1):16–27.

Bray

Ferlay

Soerjomataram

, et al: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68(6):394–424.

Cardoso

Paluch-Shimon

Senkus

, et al: 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Ann Oncol 2020;31(12):1623–1649.

Vasconcelos

Hussainzada

Berger

, et al: The St. Gallen surrogate classification for breast cancer subtypes successfully predicts tumor presenting features, nodal involvement, recurrence patterns and disease free survival. Breast 2016;29:181–185.

Early Breast Cancer Trialists’ Collaborative Group (EBCTCG): Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 2005;365(9472):1687–1717.

Gianni

Eiermann

Semiglazov

, et al: Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): A randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet 2010;375(9712):377–384.

Wang

Zhu

Liu

, et al: The clinicopathological features and survival outcomes of patients with different metastatic sites in stage IV breast cancer. BMC Cancer 2019;19(1):1091.

Savci-Heijink

Halfwerk

Hooijer

, et al: Retrospective analysis of metastatic behaviour of breast cancer subtypes. Breast Cancer Res Treat 2015;150(3):547–557.

10.

Sundén

Norgren

Lundqvist

, et al: Receptor conversion and survival in breast cancer liver metastases. Breast Cancer Res 2023;25(1):105.

11.

Chen

Qarmali

Siegal

, et al: Receptor conversion in metastatic breast cancer: Analysis of 390 cases from a single institution. Mod Pathol 2020;33(12):2499–2506.

12.

Hoefnagel

Moelans

Meijer

, et al: Prognostic value of estrogen receptor α and progesterone receptor conversion in distant breast cancer metastases. Cancer 2012;118:4929–4935.

13.

Jin

Jiang

Chen

, et al: Prognostic value of receptor conversion after neoadjuvant chemotherapy in breast cancer patients: A prospective observational study. Oncotarget 2015;6:9600–9611.

14.

Meng

Song

Jiang

, et al: Receptor conversion in metastatic breast cancer: A prognosticator of survival. Oncotarget 2016;7:71887–71903.

15.

Elsberger

Roxburgh

Horgan

: Is there a role for surgical resections of hepatic breast cancer metastases? Hepatogastroenterology 2014;61(129):181–186.

16.

Bacalbasa

Dima

Purtan-Purnichescu

, et al: Role of surgical treatment in breast cancer liver metastases: A single center experience. Anticancer Res 2014;34(10):5563–5568.

17.

Vertriest

Berardi

Tomassini

, et al: Resection of single metachronous liver metastases from breast cancer stage I-II yield excellent overall and disease-free survival. Single center experience and review of the literature. Dig Surg 2015;32(1):52–59.

18.

Chen

Lee

, et al: Does hepatectomy improve outcomes of breast cancer with liver metastasis? A nationwide analysis of real-world data in Taiwan. PLoS ONE 2022;17(4):e0266960.

19.

Ruiz

van Hillegersberg

Siesling

, et al: Surgical resection versus systemic therapy for breast cancer liver metastases: Results of a European case matched comparison. Eur J Cancer 2018;95:1–10.

20.

Mariani

Servois

De Rycke

, et al: Liver metastases from breast cancer: Surgical resection or not? A case-matched control study in highly selected patients. Eur J Surg Oncol 2013;39(12):1377–1383.

21.

Sundén

Hermansson

Taflin

, et al: Surgical treatment of breast cancer liver metastases—a nationwide registry-based case control study. Eur J Surg Oncol 2020;46(6):1006–1012.

22.

Chai

Chen

Liu

, et al: Improved survival in patients with isolated liver metastasis at initial diagnosis with surgery at primary and metastatic sites: A population-based study in patients with breast cancer. Thorac Cancer 2023;14(27):2793–2803.

23.

Abbas

Erridge

Sodergren

, et al: Breast cancer liver metastases in a UK tertiary centre: Outcomes following referral to tumour board meeting. Int J Surg 2017;44:152–159.

24.

Sadot

Lee

Sofocleous

, et al: Hepatic resection or ablation for isolated breast cancer liver metastasis: A case-control study with comparison to medically treated patients. Ann Surg 2016;264(1):147–154.

25.

Chun

Mizuno

Cloyd

, et al: Hepatic resection for breast cancer liver metastases: Impact of intrinsic subtypes. Eur J Surg Oncol 2020;46(9):1588–1595.

26.

Feng

Zhou

, et al: Comparison of hepatic resection and systemic treatment of breast cancer liver metastases: A propensity score matching study. Am J Surg 2020;220(4):945–951.

27.

Hing

Mok

Tan

, et al: Clinical utility of tumour marker velocity of cancer antigen 15-3 (CA 15-3) and carcinoembryonic antigen (CEA) in breast cancer surveillance. Breast 2020;52:95–101.

28.

Strauss

Chmura SJ: Oligometastatic breast cancer. Semin Radiat Oncol 2022;32(3):282–290.

29.

Schulz

Viktil

Godt

, et al: Diagnostic performance of CT, MRI and PET/CT in patients with suspected colorectal liver metastases: The superiority of MRI. Acta Radiol 2016;57(9):1040–1048.

30.

Detterbeck

Grodzki

Gleeson

, et al: Imaging requirements in the practice of pulmonary metastasectomy. J Thorac Oncol 2010;5(6 suppl 2):S134–S139.

31.

Gregory

Dioguardi Burgio

Corrias

, et al: Evaluation of liver tumour response by imaging. JHEP Rep 2020;2(3):100100.

32.

Zablotska

Neugut AI: Lung carcinoma after radiation therapy in women treated with lumpectomy or mastectomy for primary breast carcinoma. Cancer 2003;97(6):1404–1411.

33.

Matsuura

Itamoto

Noma

, et al: Significance of lung biopsy for the definitive diagnosis of lung nodules in breast cancer patients. Mol Clin Oncol 2018;8(2):250–256.

34.

Wennstig

Wadsten

Garmo

, et al: Risk of primary lung cancer after adjuvant radiotherapy in breast cancer-a large population-based study. NPJ Breast Cancer 2021;7(1):71.

35.

Bazire

De Rycke

Asselain

, et al: Risks of second malignancies after breast cancer treatment: Long-term results. Cancer Radiother 2017;21(1):10–15.

36.

National Library of Medicine: BreCLIM-2—a RCT investigating local treatment for breast cancer liver metastases (BreCLIM-2). https://clinicaltrials.gov/study/NCT04079049 (2024, accessed February 20, 2025)

37.

Calpin

Davey

Calpin

, et al: The impact of liver resection on survival for patients with metastatic breast cancer—A systematic review and meta-analysis. Surgeon 2023;21(4):242–249.

38.

Lin

Wang

, et al: Comparison of liver resection and radiofrequency ablation in long-term survival among patients with early-stage hepatocellular carcinoma: A meta-analysis of randomized trials and high-quality propensity score-matched studies. World J Surg Oncol 2024;22(1):56.

39.

Cervantes

Adam

Roselló

, et al: Metastatic colorectal cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol 2023;34(1):10–32.

40.

Gui

Baey

D’cruz

, et al: Trans-arterial chemoembolization + radiofrequency ablation versus surgical resection in hepatocellular carcinoma—a meta-analysis. Eur J Surg Oncol 2020;46(5):763–771.

41.

Zou

Luo

, et al: Retrospective comparative survival analysis of ablation plus systemic therapy versus systemic therapy alone for breast cancer liver metastases, stratified by extrahepatic metastases status. Breast 2025;79:103876.

42.

Vogl

Freichel

Gruber-Rouh

, et al: Interventional oncological treatment of breast cancer liver metastasis (BCLM): Single center long-term evaluation over 26 years using thermoablation techniques like LITT, MWA and TACE in a multimodal application. Int J Hyperthermia 2023;40(1):2200582.

43.

Orsi

: Interventional oncology in breast cancer. J Med Imaging Radiat Oncol 2023;67(8):876–885.

44.

Aoki

Yamashita

Abe

, et al: Stereotactic body radiotherapy (SBRT) for oligo-metastatic liver metastases from breast cancer, as an effective and safe alternative to surgery: A review. Transl Cancer Res 2020;9(8):5087–5095.

45.

Franceschini

Franzese

Comito

, et al: Definitive results of a prospective non-randomized phase 2 study on stereotactic body radiation therapy (SBRT) for medically inoperable lung and liver oligometastases from breast cancer. Radiother Oncol 2024;195:110240.

46.

Handy

Bremner

Crocenzi

, et al: Expert consensus document on pulmonary metastasectomy. Ann Thorac Surg 2019;107(2):631–649.

47.

Meimarakis

Rüttinger

Stemmler

, et al: Prolonged overall survival after pulmonary metastasectomy in patients with breast cancer. Ann Thorac Surg 2013;95(4):1170–1180.

48.

Yhim

Han

, et al: Prognostic factors for recurrent breast cancer patients with an isolated, limited number of lung metastases and implications for pulmonary metastasectomy. Cancer 2010;116(12):2890–2901.

49.

Soh

Komoike

Mitsudomi

: Surgical therapy for pulmonary metastasis of breast cancer. Transl Cancer Res 2020;9(8):5044–5052.

50.

Christ

Alongi

Ricardi

, et al: Cancer-specific dose and fractionation schedules in stereotactic body radiotherapy for oligometastatic disease: An interim analysis of the EORTC-ESTRO E2-RADIatE OligoCare study. Radiother Oncol 2024;195:110235.

51.

Alongi

Nicosia

Ricardi

, et al: Acute toxicity in patients with oligometastatic cancer following metastasis-directed stereotactic body radiotherapy: An interim analysis of the E2-RADIatE OligoCare cohort. Radiother Oncol 2024;199:110466.

52.

Chierici

Vinci

Liddo

, et al: Multimodal treatment improves survival in patients with lung metastases from colorectal cancer: A network meta-analysis. Colorectal Dis 2025;27(1):e70002.

53.

Meng

Han

, et al: CT-guided microwave ablation in patients with lung metastases from breast cancer. Thorac Cancer 2021;12(24):3380–3386.

54.

Chmura

: NRG-BR002: A phase IIR/III trial of standard of care systemic therapy with or without stereotactic body radiotherapy (SBRT) and/or surgical resection (SR) for newly oligometastatic breast cancer (NCT02364557). JCO 2022;40:1007.

55.

Cardoso

Paluch-Shimon

Schumacher-Wulf

, et al: 6th and 7th International consensus guidelines for the management of advanced breast cancer (ABC guidelines 6 and 7). Breast 2024;76:103756.

56.

Pasquier

Bidaut

Oprea-Lager

, et al: Designing clinical trials based on modern imaging and metastasis-directed treatments in patients with oligometastatic breast cancer: A consensus recommendation from the EORTC imaging and breast cancer groups. Lancet Oncol 2023;24(8):e331–e343.

57.

Linderholm

Valachis

Gordon Flote

, et al: 259 TiP treatment of oligometastatic breast cancer (OMBC): A randomised phase III trial comparing stereotactic ablative radiotherapy (SABR) and systemic treatment with systemic treatment alone as first-line treatment—TAORMINA. ESMO Open 2023;8(1):101447.

58.

Glemarec

Lacaze

Cabarrou

, et al: Systemic treatment with or without ablative therapies in oligometastatic breast cancer: A single institution analysis of patient outcomes. Breast 2023;67:102–109.[Erratum in: Breast 2023;69:424-427.]

59.

Cullinane

Fleming

O’Leary

, et al: Association of circulating tumor DNA with disease-free survival in breast cancer: A systematic review and meta-analysis. JAMA Netw Open 2020;3(11):e2026921.

60.

Garcia-Murillas

Cutts

Walsh-Crestani

, et al: Longitudinal monitoring of circulating tumor DNA to detect relapse early and predict outcome in early breast cancer. Breast Cancer Res Treat 2025;209(3):493–502.

61.

Turner

Swift

Jenkins

, et al: Results of the c-TRAK TN trial: A clinical trial utilising ctDNA mutation tracking to detect molecular residual disease and trigger intervention in patients with moderate- and high-risk early-stage triple-negative breast cancer. Ann Oncol 2023;34(2):200–211.

62.

Pusztai

Kalashnikova

Hobbs

, et al: Circulating tumor DNA (ctDNA) monitoring of estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) high risk breast cancer during adjuvant endocrine therapy. Cancer Res 2024;84:PS06–PS02.

63.

Tan

Zhang

Huang

, et al: AI models predicting breast cancer distant metastasis using LightGBM with clinical blood markers and ultrasound maximum diameter. Sci Rep 2024;14(1):15561.

Surgery for breast cancer liver and lung metastases: A review

Abstract

Background and objective:

Method:

Results:

Conclusion:

Keywords

Context and relevance

Introduction

Diagnosis of breast cancer metastases

Outcome of surgery for liver metastases

Ablation, transarterial treatment, and radiotherapy of liver metastases

Outcome of surgery for lung metastases

Radiotherapy and ablation for lung metastases

Discussion

Footnotes

Author contributions

Authors’ note

Declaration of conflicting interests

Funding

ORCID iDs

References